<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04625270</url>
  </required_header>
  <id_info>
    <org_study_id>VS-6766-201</org_study_id>
    <secondary_id>GOG-3052</secondary_id>
    <secondary_id>ENGOT-ov60</secondary_id>
    <nct_id>NCT04625270</nct_id>
  </id_info>
  <brief_title>A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation</brief_title>
  <acronym>RAMP-201</acronym>
  <official_title>A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GOG Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of VS-6766 monotherapy and in combination with&#xD;
      Defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, open-label Phase 2 study designed to evaluate safety and&#xD;
      tolerability and preliminary efficacy of VS-6766 versus VS-6766 in combination with&#xD;
      defactinib in subjects with molecularly profiled recurrent LGSOC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Determine optimal regimen of VS-6766 monotherapy or in combination with defactinib</measure>
    <time_frame>From start of treatment to confirmation of response; 24 weeks</time_frame>
    <description>Confirmed overall response rate per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: To determine the efficacy of the optimal regimen identified from Part A</measure>
    <time_frame>From start of treatment to confirmation of response; 24 weeks</time_frame>
    <description>Confirmed overall response rate per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate as assessed by Investigator</measure>
    <time_frame>From start of treatment to confirmation of response; 24 weeks</time_frame>
    <description>Proportioned subjects achieving a CR or PR as assess by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the first documentation of response to first documentation of progressive disease or death due to any cause, greater than or equal to 6 months</time_frame>
    <description>From time of first response to PD as assessed by the BIRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Greater than or equal to 8 weeks</time_frame>
    <description>CR+PR+stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>From time of first dose of study intervention to PD or death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>From time of first dose of study intervention to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the optimal regimen, either VS-6766 monotherapy or VS-6766 in combination with defactinib, for subsequent evaluation for efficacy in the Expansion Phase (Part B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the efficacy of the optimal regimen identified from Part A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS-6766</intervention_name>
    <description>VS-6766 Monotherapy</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS-6766 and Defactinib</intervention_name>
    <description>VS-6766 and Defactinib Combination</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <other_name>VS-6766 and VS-6063</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven LGSOC (ovarian, peritoneal)&#xD;
&#xD;
          -  In Part A KRAS mutation, KRAS wt&#xD;
&#xD;
          -  Progression or recurrence of LGSOC after at least one prior systemic therapy for&#xD;
             metastatic disease.&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1&#xD;
&#xD;
          -  An Eastern Cooperative Group (ECOG) performance status ≤ 1.&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Adequate recovery from toxicities related to prior treatments&#xD;
&#xD;
          -  Agreement to use highly effective method of contraceptive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy&#xD;
&#xD;
          -  Co-existing high-grade ovarian cancer or another histology&#xD;
&#xD;
          -  History of prior malignancy with recurrence &lt;3 years from the time of enrollment&#xD;
&#xD;
          -  Major surgery within 4 weeks&#xD;
&#xD;
          -  Symptomatic brain metastases requiring steroids or other interventions&#xD;
&#xD;
          -  Known SARS-Cov2 infection (clinical symptoms) ≤28 days prior to first dose of study&#xD;
             therapy&#xD;
&#xD;
          -  For subjects with prior MEK exposure, Grade 4 toxicity deemed related to the MEK&#xD;
             inhibitor&#xD;
&#xD;
          -  Active skin disorder that has required systemic therapy within the past year&#xD;
&#xD;
          -  History of rhabdomyolysis&#xD;
&#xD;
          -  Concurrent ocular disorders&#xD;
&#xD;
          -  Concurrent heart disease or severe obstructive pulmonary disease&#xD;
&#xD;
          -  Subjects with the inability to swallow oral medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susana Banerjee, MBBS,MA,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Network of Gynaecological Oncological Trial Groups (ENGOT)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachel Grisham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GOG Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagop Youssoufian, MSc, MD</last_name>
    <role>Study Director</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate Adams-Loeffler</last_name>
    <phone>781-469-1038</phone>
    <email>kadams@verastem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gloria Patrick</last_name>
    <phone>781-469-1594</phone>
    <email>gpatrick@verastem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Oncology Associates PC HAL</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Szilvagyi</last_name>
      <email>Jonathan.Szilvagyi@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Bradley J Monk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Heitkamp</last_name>
      <phone>805-879-0643</phone>
      <email>hheitkam@ridleytreecc.org</email>
    </contact>
    <investigator>
      <last_name>Gregg Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Baker</last_name>
      <email>lisa.baker@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Alessandro Santin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Diaz</last_name>
      <phone>786-596-2000</phone>
      <email>johnpd@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>John Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advent Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Coakley</last_name>
      <email>Susan.Coakley@AdventHealth.com</email>
    </contact>
    <investigator>
      <last_name>Robert Holloway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute - Center for Women's Oncology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaToya Hyde</last_name>
      <email>Latoya.Hyde@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hye Sook Chon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hatti Koning</last_name>
      <email>hkoning@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>John Maroney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Anderson</last_name>
      <email>Lynn.Anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Emily Prendergast, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Russell</last_name>
      <email>swrussell@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Premal Thaker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Lovelace</last_name>
      <email>ann.lovelace@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anu Thummala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Comprehensive Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Byatt</last_name>
      <email>lpbyatt@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Carolyn Muller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Grisham</last_name>
      <phone>646-888-4653</phone>
    </contact>
    <investigator>
      <last_name>Rachel Grisham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Women's Health Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna White</last_name>
      <email>Whited11@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Peter Rose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Hwang</last_name>
      <email>Sarah.Hwang@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Kristin Bixel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Pappaterra</last_name>
      <email>Christine-Pappaterra@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roosevelt Anderson</last_name>
      <email>Roosevelt.Anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Charles Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Salinas</last_name>
      <phone>503-280-1223</phone>
    </contact>
    <investigator>
      <last_name>Erin Salinas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mythili Shastry</last_name>
      <email>Mythili.Shastry@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin Central</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Arellano</last_name>
      <email>Monica.Arellano@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Marian Heave</last_name>
      <email>Marian.Heave@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Micheal Teneriello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Thomas</last_name>
      <email>Tiffany.Thomas@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Poe</last_name>
      <email>Karen.Poe@USOncology.com</email>
    </contact>
    <investigator>
      <last_name>Anna M Priebe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nereida Salinas</last_name>
      <email>nereida.salinas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Suresh Ratnam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora Lind</last_name>
      <email>Debora.Lind@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Santillian-Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veta Clayton</last_name>
      <email>Veta.Clayton@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christine Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <email>AM7BD@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Kari Ring, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurey Wilcox</last_name>
      <email>maurey.wilcox@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mitul Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Gainesville</city>
        <state>Virginia</state>
        <zip>20155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <email>Marcy.Sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Mitul Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Els Nieuwenhuysen</last_name>
      <phone>32 16 34 51 28</phone>
      <email>els.vannieuwenhuysen@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Els Van Nieuewenhuysen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM - Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Fabbro</last_name>
      <phone>33 (0)4 67 61 30 63</phone>
      <email>michel.fabbro@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Michel Fabbro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Simpson</last_name>
      <phone>0131 537 1234</phone>
      <email>Ryan.Simpson@nhslothian.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Charlie Gourley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G120YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon Fairley</last_name>
      <email>shannon.fairley@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Rosalind Glasspool, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLH Cancer Clinical Trials Unit</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Hawkes-Blackburn</last_name>
      <phone>07790 895740</phone>
      <email>m.hawkes-blackburn@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Rowan Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Clamp</last_name>
      <email>andrew.clamp@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Andrew Clamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylie Fitch</last_name>
    </contact>
    <contact_backup>
      <last_name>Kylie.Fitch@rmh.nhs.uk</last_name>
    </contact_backup>
    <investigator>
      <last_name>Susana Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Grade Serous Ovarian Cancer</keyword>
  <keyword>KRAS, KRAS wt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

